Last reviewed · How we verify

[89Zr]Zr-crefmirlimab berdoxam (89zr-zr-crefmirlimab-berdoxam)

Pfizer · FDA-approved active Monoclonal antibody Quality 26/100

[89Zr]Zr-crefmirlimab berdoxam (generic name: 89zr-zr-crefmirlimab-berdoxam) is a Radiolabeled Monoclonal Antibody Monoclonal antibody drug developed by Pfizer. It is currently FDA-approved (first approved Not ) for Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy.

89Zr-Zr-crefmirlimab berdoxam is a radiolabeled antibody developed by Pfizer Inc. for imaging purposes. It is not approved by the FDA and is currently in the pipeline for various oncology applications. The drug targets fibroblast activation protein (FAP) and is designed to help visualize tumors that express this protein. Due to its radiolabeled nature, it may have specific safety considerations, including radiation exposure. The drug is part of a broader class of targeted radiopharmaceuticals and represents a novel approach in cancer imaging.

At a glance

Generic name89zr-zr-crefmirlimab-berdoxam
SponsorPfizer
Drug classRadiolabeled Monoclonal Antibody
TargetFibroblast Activation Protein (FAP)
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approvalNot specified

Approved indications

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about [89Zr]Zr-crefmirlimab berdoxam

What is [89Zr]Zr-crefmirlimab berdoxam?

[89Zr]Zr-crefmirlimab berdoxam (89zr-zr-crefmirlimab-berdoxam) is a Radiolabeled Monoclonal Antibody drug developed by Pfizer, indicated for Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy.

What is [89Zr]Zr-crefmirlimab berdoxam used for?

[89Zr]Zr-crefmirlimab berdoxam is indicated for Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy.

Who makes [89Zr]Zr-crefmirlimab berdoxam?

[89Zr]Zr-crefmirlimab berdoxam is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of [89Zr]Zr-crefmirlimab berdoxam?

89zr-zr-crefmirlimab-berdoxam is the generic (nonproprietary) name of [89Zr]Zr-crefmirlimab berdoxam.

What drug class is [89Zr]Zr-crefmirlimab berdoxam in?

[89Zr]Zr-crefmirlimab berdoxam belongs to the Radiolabeled Monoclonal Antibody class. See all Radiolabeled Monoclonal Antibody drugs at /class/radiolabeled-monoclonal-antibody.

When was [89Zr]Zr-crefmirlimab berdoxam approved?

[89Zr]Zr-crefmirlimab berdoxam was first approved on Not specified.

What development phase is [89Zr]Zr-crefmirlimab berdoxam in?

[89Zr]Zr-crefmirlimab berdoxam is FDA-approved (marketed).

What does [89Zr]Zr-crefmirlimab berdoxam target?

[89Zr]Zr-crefmirlimab berdoxam targets Fibroblast Activation Protein (FAP) and is a Radiolabeled Monoclonal Antibody.

Related